Skip to main content
. 2021 Apr 8;2021:1929357. doi: 10.1155/2021/1929357

Table 1.

Clinical characteristics of de novo non-M3 AML patients according to the CD56 expression.

Variables All patients, n (%) CD56-low, n (%) CD56-high, n (%) P value
No. of patients 89 (100) 63 (70.79) 26 (29.21)
Sex
 Male 42 (47.19) 24 (38.10) 18 (69.23) 0.343
 Female 47 (52.81) 39 (61.90) 8 (30.77)
Age, years 0.143
 Mean (min-max) 39 (12~64) 41 (13~64) 36 (12~61)
BM blasts (%) 0.244
 Median 67.70 63.39 73.20
 Range 15.57~97.25 15.57~97.25 33.50~95.00
WBC (×109/L) 0.632
 Mean (min-max) 39.76 (0.59~365.67) 41.55 (0.95~365.67) 35.19 (1.28~148.90)
HB (g/dL) 0.336
 Mean (min-max) 76.03 (1.78~149.00) 77.71 (1.78~149.00) 71.65 (37~107)
PLT (×109/L) 0.010
 Median 27.00 32.5 21.5
 Range 3~301 3~301 5~83
FAB classification 0.471
 M1 9 (10.11) 5 (7.94) 4 (15.38)
 M2 27 (30.34) 20 (31.75) 7 (26.92)
 M4 28 (31.46) 24 (38.10) 4 (15.38)
 M5 15 (16.85) 11 (17.46) 4 (15.38)
 Unclassified 5 (5.62) 3 (4.76) 2 (7.69)
Cytogenetic risk 0.274
 Favorable 9 (10.11) 5 (7.94) 4 (15.38)
 Intermediate 61 (68.54) 43 (68.25) 18 (69.23)
 Adverse 19 (21.35) 15 (23.81) 4 (15.38)
Received BMT 1.000
 BMT 15 (16.85) 11 (17.46) 4 (15.38)
 Without BMT 74 (83.15) 52 (82.54) 22 (84.62)

BM: bone marrow; WBC: white blood cell; Hb: hemoglobin; PLT: platelet; BMT: bone marrow transplantation.